LifeMD, Inc. (NASDAQ:LFMD) Receives $11.57 Average PT from Analysts

LifeMD, Inc. (NASDAQ:LFMD) has been given an average rating of “Moderate Buy” by the seven research firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $11.57.

A number of equities research analysts have recently commented on LFMD shares. Lake Street Capital started coverage on LifeMD in a research report on Tuesday, December 10th. They set a “buy” rating and a $12.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of LifeMD in a report on Monday, November 11th. Mizuho started coverage on shares of LifeMD in a report on Wednesday, December 4th. They issued a “neutral” rating and a $7.00 price target for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $15.00 price objective on shares of LifeMD in a research report on Friday, September 20th.

Insider Transactions at LifeMD

In related news, CEO Justin Schreiber sold 25,000 shares of LifeMD stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $6.52, for a total value of $163,000.00. Following the sale, the chief executive officer now owns 2,728,715 shares of the company’s stock, valued at approximately $17,791,221.80. The trade was a 0.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 15.97% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. State Street Corp raised its stake in shares of LifeMD by 20.0% during the 3rd quarter. State Street Corp now owns 1,155,495 shares of the company’s stock worth $6,055,000 after purchasing an additional 192,861 shares in the last quarter. Royce & Associates LP increased its holdings in LifeMD by 14.6% during the third quarter. Royce & Associates LP now owns 901,041 shares of the company’s stock worth $4,721,000 after buying an additional 114,710 shares during the last quarter. Geode Capital Management LLC increased its holdings in LifeMD by 11.4% during the third quarter. Geode Capital Management LLC now owns 819,233 shares of the company’s stock worth $4,293,000 after buying an additional 83,598 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in LifeMD by 6.7% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 765,916 shares of the company’s stock worth $4,013,000 after acquiring an additional 48,201 shares in the last quarter. Finally, Cubist Systematic Strategies LLC lifted its stake in LifeMD by 15.1% in the second quarter. Cubist Systematic Strategies LLC now owns 551,344 shares of the company’s stock valued at $3,782,000 after acquiring an additional 72,203 shares during the last quarter. 35.52% of the stock is currently owned by institutional investors.

LifeMD Stock Performance

Shares of LifeMD stock opened at $5.31 on Friday. LifeMD has a 12 month low of $3.99 and a 12 month high of $12.88. The company has a current ratio of 0.83, a quick ratio of 0.78 and a debt-to-equity ratio of 10.83. The company has a market capitalization of $229.99 million, a PE ratio of -8.30 and a beta of 1.38. The stock’s fifty day simple moving average is $5.41 and its 200 day simple moving average is $5.72.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.